Drug Profile

N-Methyltryptamine - Core One Labs

Alternative Names: Monomethyltryptamine - Core One Labs; N-Monomethyltryptamine - Core One Labs; NMT - Core One Labs

Latest Information Update: 16 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Core One Labs
Developer Core One Labs; Vocan Biotechnologies
Class Alkaloids; Antipsychotics; Indoles; Methylamines; Neuropsychotherapeutics; Tryptamines
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

16 Mar 2022 Early research in Unspecified in Canada (unspecified route)
21 Feb 2022 Core One Labs files patent for protection for N-methyltryptamine
28 Apr 2021 Core One Labs and Lobe Sciences enters into a letter of intent for the formation of a joint venture for the development, regulatory approval, marketing, sale and distribution of biosynthetic psilocybin and other psychedelic compounds

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com